Tetsuji Kurokawa

Dr. Tetsuji Kurokawa

Department of Obstetrics and Gynecology, University of Fukui, Fukui, Japan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
YYYoshio Yoshida
Yoshio Yoshida
TKTetsuji Kurokawa
Tetsuji Kurokawa
TTTetsuya Tsujikawa
Tetsuya Tsujikawa
Hidehiko OkazawaHidehiko Okazawa
Hidehiko Okazawa
FKFumikazu Kotsuji
Fumikazu Kotsuji
The most frequently used molecular imaging technique is currently 18F-deoxy-glucose (FDG) positron emission tomography (PET). FDG-PET holds promise in the evaluation of recurrent or residual ovarian cancer when CA125 levels are rising and conventional imaging, such as ultrasound, CT, or MRI, is inconclusive or negative. Recently, integrated PET/CT, in which a full-ring-detector clinical PET scanner and a multidetector helical CT scanner are combined, has enabled the acquisition of both metabolic and anatomic imaging data using one device in a single diagnostic session. This can also provide precise anatomic localization of suspicious areas of increased FDG uptake and rule out false-positive PET findings. FDG-PET/CT is an accurate modality for assessing primary and recurrent ovarian cancer and may affect management. FDG-PET/CT may provide benefits for detection of recurrent of ovarian cancer and improve surgical planning. And FDG-PET has been shown to predict response to neoadjuvant chemotherapy and survival in advanced ovarian cancer. This review focuses on the role of FDG-PET and FDG-PET/CT in the management of patients with ovarian cancer. Recently, we have evaluated 16α-18F-fluoro-17β-estradiol (FES)-PET, which detects estrogen receptors. In a preliminary study we reported that FES-PET provides information useful for assessing ER status in advanced ovarian cancer. This new information may expand treatment choice for such patients.

15 April 2008 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
YYYoshio Yoshida
Yoshio Yoshida
TKTetsuji Kurokawa
Tetsuji Kurokawa
YSYoko Sawamura
Yoko Sawamura
ASAkiko Shinagawa
Akiko Shinagawa
TTTetsuya Tsujikawa
Tetsuya Tsujikawa
FKFumikazu Kotsuji
Fumikazu Kotsuji
The purpose of this study was to prospectively determine whether combined MRI and 18F-FDG PET is more accurate than MRI in assessing nonbenign uterine smooth muscle tumors (USMTs). Methods: Seventy patients (mean age, 49 ± 10 y; range, 28–77 y) suspected of having nonbenign USMTs underwent both MRI and 18F-FDG PET before surgery. Results were evaluated using receiver-operating-characteristic (ROC) analyses and the Cochran Q test. Results: The area under the ROC curve for MRI with 18F-FDG PET was significantly higher than that for MRI (0.97 vs. 0.89, P < 0.05). Although multiple comparisons using the Cochran Q test were not significant, the sensitivity, specificity, and accuracy for MRI with 18F-FDG PET with probable nonbenign USMT cases considered to be positive were higher than those for MRI (93.3% vs. 73.3%; 92.7% vs. 85.5%; and 92.9% vs. 82.9%, respectively). Conclusion: MRI with 18F-FDG PET is useful in assessing nonbenign USMTs, as compared with MRI.

1 March 2008 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
YYYoshio Yoshida
Yoshio Yoshida
TKTetsuji Kurokawa
Tetsuji Kurokawa
YNYukiko Nishikawa
Yukiko Nishikawa
MOMakoto Orisa
Makoto Orisa
HKHynda K Kleinman
Hynda K Kleinman
FKFumikazu Kotsuji
Fumikazu Kotsuji
We found previously that the laminin-1-derived synthetic peptide AG73 (LQVQLSIR) promoted ovarian cancer cell metastasis in vivo. We have now studied the role of this metastasis-promoting peptide in vitro using TAC3 ovarian cancer cells, which display anchorage-independent growth and form multicellular spheroids. Our goal is to better understand how this peptide can regulate metastasis in vivo. We found that the exogenous addition of either laminin-1 or peptide AG73 stimulated the formation and growth of the spheroids. Western blot analysis indicated that laminin-1 enhanced the expression of integrin beta1, and that AG73 peptide enhanced expression of syndecan-1 and downstream effectors, including mitogen-activated protein kinase (MAPK) and extracellular signal-related kinase (ERK), and also phosphatidylinositol (PI)-3 kinase/AKT activity signaling. The soluble peptide AG73T, which is a scramble peptide of AG73, was able to disaggregate the laminin-1-induced spheroids. Furthermore, the disaggregated cells were twice as sensitive to cisplatin as the intact spheroids. The AG73T peptide in the presence of laminin-1 suppressed expression of integrin beta1 and its downstream effectors, including MAPK/ERK and PI3/AKT activity signaling. The MEK inhibitor U0126 reduced TAC3 cell growth more effectively in the presence of both laminin-1 and AG73T than in the presence of laminin-1 alone. Inhibition of the PI3-K cascade with LY294002 was also more effective in the presence of laminin-1 and AG73T. The increased sensitivity to cisplatin in the presence of AG73T may be due to the greater bioavailability of the drug to the free-floating cells over the spheroids. These findings suggest a novel function of AG73T in ovarian cancer and help to define mechanisms important in ovarian cancer spheroid formation and spread.

21 June 2018 in Cytopathology
Verified
Journal Article
Open access
TKTetsuji Kurokawa
Tetsuji Kurokawa
TOT. Onuma
T. Onuma
ASA. Shinagawa
A. Shinagawa
YCY. Chino
Y. Chino
MKM. Kobayashi
M. Kobayashi
YYY. Yoshida
Y. Yoshida
Introduction: The aims of the Fukui Cervical Cancer Screening (FCCS) study are to determine the frequency of women with high‐risk HPV (hrHPV), whether HPV16 or HPV18 (HPV16/18), in the Japanese cancer screening population for the first time and to identify the best strategy for cervical cancer screening in Japan.Methods: This study enrolled 7584 women aged ≥25 years who were undergoing routine screening. All women underwent LBC and cobas HPV tests. Women with abnormal cytology, whether hrHPV positive or negative; women with hrHPV positivity with either normal or abnormal cytology; and women randomly selected from women with normal cytology and negative hrHPV negative were referred for colposcopy.Results: The prevalences of hrHPV positivity and HPV16/18 positivity were 6.8% and 1.7%, respectively. The baseline data from the FCCS study showed that the combination of HPV tests and cytology was more sensitive than cytology with respect to the detection of intraepithelial neoplasia grade 2 or worse. However, the specificity (94.1%) of the co‐testing strategy that required all women with abnormal cytology or hrHPV positivity to be referred for colposcopy was much lower than that (97.8%) of cytology. The sensitivity and specificity of the co‐testing strategy that required only women with abnormal cytology or HPV16/18 positivity to undergo colposcopy were 85.5% and 97.0%, respectively.Conclusion: The baseline data from the FCCS study suggest that a cervical cancer screening strategy in which only women with abnormal cytology or HPV16/18 positivity undergo colposcopy offers a more balanced sensitivity and specificity than other strategies.

1 December 2017 in International Journal of Surgery
Verified
Journal Article
Closed access
KKKazumi Kurata
Kazumi Kurata
YCYoko Chino
Yoko Chino
ASAkiko Shinagawa
Akiko Shinagawa
TKTetsuji Kurokawa
Tetsuji Kurokawa
YYYoshio Yoshida
Yoshio Yoshida
The aim of this study was to determine whether a preoperative health status index and intraoperative data could predict perioperative morbidity and mortality in women over the age of 65 years undergoing surgery for gynecologic disorders. The medical records of 68 female patients who were ≥65 years of age and who underwent surgery under general anesthesia in our institute from January 2014 to December 2015 were retrospectively reviewed. Preoperative data were extracted from a database and included comorbidities, American Society of Anesthesiologists physiological status classification, the Charlson Comorbidity Index, the Subjective Global Assessment 2011 revision, the subjects' risk of falling, body mass index, and age. The intraoperative factors investigated included the type of surgery and the Surgical Apgar Score (SAS). Major postoperative complications were defined as > Grade 3 based on the Clavien-Dindo classification version 2.0. Of the 68 elderly gynecological patients, 6 (8.8%) developed serious Grade 3 or worse complications within 30 days of surgery. The only factor that significantly affected postoperative complications was the SAS, an index of the patient's intraoperative condition. The optimum cut-off SAS for the occurrence of complications was determined by the receiver operating characteristic curve to be ≤ 6 points; a score ≤6 points predicted the development of postoperative complications with 66.7% sensitivity and 79.0% specificity. In this study, the SAS predicted the development of serious complications in elderly gynecological patients within 30 days of surgery more accurately than did other comorbidities, preoperative assessments, and type of surgery.

19 February 2018 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
ASAkiko Shinagawa
Akiko Shinagawa
TKTetsuji Kurokawa
Tetsuji Kurokawa
MYMakoto Yamamoto
Makoto Yamamoto
TOToshimichi Onuma
Toshimichi Onuma
HTHideaki Tsuyoshi
Hideaki Tsuyoshi
YYYoshida Yoshio
Yoshida Yoshio